Used in research and development for targeting PAI-1 (plasminogen activator inhibitor-1) in fibrotic diseases, cardiovascular conditions, and cancer. This antibody helps neutralize PAI-1 activity, promoting fibrinolysis and reducing extracellular matrix accumulation. It has been explored in preclinical models for lung, liver, and kidney fibrosis, as well as in thrombosis and tumor progression studies. Its high specificity makes it valuable for assay development, biomarker validation, and therapeutic candidate evaluation.